NO20064200L - Fremgangsmate for syntese av en CXCR4-antagonist - Google Patents
Fremgangsmate for syntese av en CXCR4-antagonistInfo
- Publication number
- NO20064200L NO20064200L NO20064200A NO20064200A NO20064200L NO 20064200 L NO20064200 L NO 20064200L NO 20064200 A NO20064200 A NO 20064200A NO 20064200 A NO20064200 A NO 20064200A NO 20064200 L NO20064200 L NO 20064200L
- Authority
- NO
- Norway
- Prior art keywords
- protected
- synthesis
- amine
- imine
- reacting
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 title 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical group CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 abstract 2
- 150000002466 imines Chemical class 0.000 abstract 2
- 150000003335 secondary amines Chemical class 0.000 abstract 2
- SHQUNUAMNCPZNJ-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinolin-2-amine Chemical compound C1CCCC2=NC(N)=CC=C21 SHQUNUAMNCPZNJ-UHFFFAOYSA-N 0.000 abstract 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- -1 haloalkyl substituted heterocyclic compound Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 125000005543 phthalimide group Chemical group 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55358904P | 2004-03-15 | 2004-03-15 | |
| PCT/US2005/008268 WO2005090308A1 (en) | 2004-03-15 | 2005-03-11 | Process for the synthesis of a cxcr4 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064200L true NO20064200L (no) | 2006-09-15 |
Family
ID=34993619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064200A NO20064200L (no) | 2004-03-15 | 2006-09-15 | Fremgangsmate for syntese av en CXCR4-antagonist |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7332605B2 (pt) |
| EP (1) | EP1730113B1 (pt) |
| JP (1) | JP4870660B2 (pt) |
| KR (1) | KR20060131899A (pt) |
| CN (1) | CN1930127B (pt) |
| AU (1) | AU2005224079A1 (pt) |
| BR (1) | BRPI0508703B8 (pt) |
| CA (1) | CA2558389C (pt) |
| ES (1) | ES2614508T3 (pt) |
| IL (1) | IL177511A (pt) |
| NO (1) | NO20064200L (pt) |
| RU (1) | RU2006136381A (pt) |
| WO (1) | WO2005090308A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2006023400A2 (en) * | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
| TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| PE20070946A1 (es) * | 2006-01-25 | 2007-10-16 | Smithkline Beecham Corp | COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4) |
| JP2009524689A (ja) * | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US20100003224A1 (en) * | 2006-08-02 | 2010-01-07 | Genzyme Corporation | Combination Therapy |
| WO2008134326A1 (en) * | 2007-04-26 | 2008-11-06 | Dow Global Technologies Inc. | Novel aldehyde composition |
| FR2934859B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| MY170236A (en) | 2010-10-06 | 2019-07-11 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| GB201604213D0 (en) * | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| US10548889B1 (en) * | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| JP2023524522A (ja) | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤 |
| WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
| CA3233731A1 (en) * | 2021-10-07 | 2023-04-13 | Roger Hanselmann | Synthesis of mavorixafor and intermediates thereof |
| CN116789639A (zh) * | 2022-03-14 | 2023-09-22 | 上海医药工业研究院有限公司 | Mavorixafor的纯化方法、其盐及有关物质 |
| WO2024216114A1 (en) * | 2023-04-13 | 2024-10-17 | X4 Pharmaceuticals, Inc. | Synthesis of mavorixafor and intermediates thereof |
| WO2024216075A1 (en) * | 2023-04-13 | 2024-10-17 | X4 Pharmaceuticals, Inc. | Synthesis of mavorixafor and intermediates thereof |
| WO2024216095A1 (en) * | 2023-04-13 | 2024-10-17 | X4 Pharmaceuticals, Inc. | Synthesis of mavorixafor and intermediates thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| AU740603B2 (en) * | 1997-06-02 | 2001-11-08 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
| AP1654A (en) | 1999-03-24 | 2006-09-01 | Anormed Inc | Chemokine receptor binding heterocyclic compounds. |
| US6734191B2 (en) * | 2000-09-15 | 2004-05-11 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| HK1052011A1 (zh) * | 2000-09-15 | 2003-08-29 | Anormed Inc. | 趋化因子受体结合杂环化合物 |
| CZ10903U1 (en) * | 2001-01-11 | 2001-02-19 | Oldrich Ing Cihak | Bladed water wheel |
| PL369856A1 (en) | 2001-12-21 | 2005-05-02 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
-
2005
- 2005-03-11 EP EP05725450.0A patent/EP1730113B1/en not_active Expired - Lifetime
- 2005-03-11 WO PCT/US2005/008268 patent/WO2005090308A1/en not_active Ceased
- 2005-03-11 BR BRPI0508703A patent/BRPI0508703B8/pt not_active IP Right Cessation
- 2005-03-11 CA CA2558389A patent/CA2558389C/en not_active Expired - Lifetime
- 2005-03-11 US US11/077,896 patent/US7332605B2/en not_active Expired - Lifetime
- 2005-03-11 JP JP2007503981A patent/JP4870660B2/ja not_active Expired - Lifetime
- 2005-03-11 ES ES05725450.0T patent/ES2614508T3/es not_active Expired - Lifetime
- 2005-03-11 KR KR1020067019097A patent/KR20060131899A/ko not_active Withdrawn
- 2005-03-11 AU AU2005224079A patent/AU2005224079A1/en not_active Abandoned
- 2005-03-11 CN CN2005800069769A patent/CN1930127B/zh not_active Expired - Lifetime
- 2005-03-11 RU RU2006136381/04A patent/RU2006136381A/ru not_active Application Discontinuation
-
2006
- 2006-08-16 IL IL177511A patent/IL177511A/en active IP Right Grant
- 2006-09-15 NO NO20064200A patent/NO20064200L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL177511A0 (en) | 2006-12-10 |
| AU2005224079A1 (en) | 2005-09-29 |
| BRPI0508703A (pt) | 2007-08-07 |
| US7332605B2 (en) | 2008-02-19 |
| US20050209277A1 (en) | 2005-09-22 |
| KR20060131899A (ko) | 2006-12-20 |
| EP1730113A4 (en) | 2009-12-02 |
| BRPI0508703B1 (pt) | 2020-11-24 |
| CA2558389C (en) | 2013-10-08 |
| CA2558389A1 (en) | 2005-09-29 |
| CN1930127B (zh) | 2012-11-21 |
| IL177511A (en) | 2010-12-30 |
| WO2005090308A1 (en) | 2005-09-29 |
| JP2007529526A (ja) | 2007-10-25 |
| RU2006136381A (ru) | 2008-04-27 |
| ES2614508T3 (es) | 2017-05-31 |
| CN1930127A (zh) | 2007-03-14 |
| EP1730113B1 (en) | 2016-12-28 |
| JP4870660B2 (ja) | 2012-02-08 |
| BRPI0508703B8 (pt) | 2021-05-25 |
| EP1730113A1 (en) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064200L (no) | Fremgangsmate for syntese av en CXCR4-antagonist | |
| ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
| NO341631B1 (no) | Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger | |
| BRPI0519597A2 (pt) | derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose | |
| DK1776377T3 (da) | Nyt steroid til FXR | |
| NO20076554L (no) | Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer | |
| DK2029529T3 (da) | Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1 | |
| NO20064579L (no) | Bifenylforbindelser anvendelige som muskariniske receptorantagonister | |
| DK1807072T3 (da) | Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1 | |
| MX2008014908A (es) | Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo. | |
| CY1112402T1 (el) | Ενισχυτες υποδοχεων γλουταμικου | |
| MY136959A (en) | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | |
| WO2008007113A3 (en) | Pharmaceutical combinations | |
| DE602005008558D1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen | |
| DE60235396D1 (de) | 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung | |
| NO20073701L (no) | Nye fremgangsmater for fremstilling av et 2H-kromen | |
| IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
| NO20076145L (no) | Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| GEP20084494B (en) | New heterocyclic carboxylic acid amide derivatives | |
| BRPI0510335A (pt) | composto heterocìclico | |
| PH12012502348A1 (en) | Novel spiroheterocyclic compounds as mglu5 antagonists | |
| ATE550326T1 (de) | Als modulatoren von hdl einsetzbare verbindungen | |
| NO20081529L (no) | Naftyridinderivater | |
| MY140571A (en) | Mercaptoimidazoles as ccr2 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |